Kirby McInerney LLP is investigating potential claims against the Board of Directors of Santarus, Inc. (“Santarus” or the “Company”) (NASDAQ:SNTS) concerning the proposed acquisition of the Company by Salix Pharmaceuticals, Ltd. (“Salix”). Under the terms of the proposed transaction, Santarus stockholders will receive $32.00 in cash for each share of Santarus owned, valuing the transaction at approximately $2.6 billion.

The investigation concerns whether the Santarus Board of Directors violated its fiduciary duties by agreeing to the proposed transaction and whether the $32.00 per share proposed consideration adequately values Santarus’ common stock.

If you are a Santarus stockholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at bwalker@kmllp.com, by telephone at (212) 699-1145 or (888) 529-4787, or by filling out this contact form. There is no cost or obligation to you.

Kirby McInerney LLP is a New York-based law firm concentrating in securities, stockholder, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmllp.com.

Kirby McInerney LLPJ. Brandon Walker, Esq., 212-699-1145888-529-4787bwalker@kmllp.com

Santarus (NASDAQ:SNTS)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025 Haga Click aquí para más Gráficas Santarus.
Santarus (NASDAQ:SNTS)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025 Haga Click aquí para más Gráficas Santarus.